Defending Against Plaintiffs’ Strongest Arguments Against Generic Preemption

ACI's 19th Drug & Medical Device Conference

12/10/2014 10:45 a.m. - 11:20 a.m.

Life Sciences and Product Liability

New York Marriott Marquis Hotel
1535 Broadway
New York, NY 10036

Erin M. Bosman

Erin M. Bosman

Speaking Engagement

  • Asserting a successful preemption defense and managing parallel claims in a post-Bartlett world
    • Overview of successful defense strategies in recent cases regarding parallel claims
       
    • Defending against parallel claims that aren’t deemed to be preempted
       
    • Understanding the significance of the “Footnote 4” potential exemption cases currently working their way through the Circuit Courts
       
    • Pleading standards post In re: Darvocet
  • Dissecting plaintiffs’ best arguments for getting around preemption and how the courts treated these arguments
  • Updates on legislative and FDA developments regarding generic labeling: what are the practical implications for both branded and generics based on Congress’ and FDA’s positions to date
    • What should prudent companies do in the years leading up to a potential change in preemption doctrine?
  • Utilizing an innovator liability theory when arguing for generic preemption

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.